An observational study in Breast Cancer, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.
Among the 200 studies in Breast Neoplasms by Novartis, this one is the 7th largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 12 of the 30 other live ones, and was the 197th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in Netherlands
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 6 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in China
Ages 18–99
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 54 · Phase 3 48 · Phase 4 17
First in 1998; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 104 across the 155 interventional studies, 595 across the 39 observational. Of the 160 that completed or were terminated, 74 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
11 of the studies in Breast Neoplasms by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05870579Novartis Pharmaceuticals[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | 2026-12-30 |
| NCT07945548Novartis PharmaceuticalsA Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine Learning Approach With Real-world Data | 2027-01-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
Add all 11 to your calendar (.ics) → With an account.
Among the 200 studies in Breast Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the clinical adoption, treatment patterns, and safety of adjuvant ribociclib use in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) patients. This is a multi-country study using secondary real-world data sources.
Adult patients diagnosed with HR+/HER2- eBC who have undergone surgical resection of the primary breast tumor and initiated adjuvant ET.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of HR+ during the study period:
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ET and meet additional staging criteria including either Stage III, or Stage IIB, or Stage IIA with N1, Stage IIA with N0 and Grade 3, or Stage IIA with N0 and Grade 2 and Ki-67 ≥20% or high genomic risk.
Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ribociclib in addition to ET.
Patients in Cohort B who have at least six months of potential follow-up time after ribociclib initiation at the time of the analysis.
This study also gives RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Cohort B and Subcohort B1: Proportion of Patients by Baseline Demographics and Clinical Characteristics
Baseline characteristics (subject to data availability) include: * Age group * Sex * Race/Ethnicity * Geographic region * Insurance type * Menopausal status * Body mass index (BMI) category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * Eastern Cooperative Oncology Group (ECOG) performance status * Estrogen and progesterone receptor status * HER2 immunohistochemistry (IHC) test results (0, 1+, 2+, 3+) * HER2 Fluorescence In Situ Hybridization (FISH) test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * Gastrointestinal (GI) dysfunction (yes/no)
Time frame: Baseline
Cohort B and Subcohort B1: Proportion of Patients by Demographics and Clinical Characteristics at Index Treatment Date
The index treatment date is the date of adjuvant ribociclib treatment initiation. Demographics and clinical characteristics (subject to data availability) include: * Age group * Insurance type * Menopausal status * BMI category * ECOG performance status
Time frame: Baseline
Cohort B and Subcohort B1: Charlson Comorbidity Index (CCI)
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).
Time frame: Baseline
Cohort B and Subcohort B1: AST Levels at Index Diagnosis Date and Index Treatment Date
Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.
Time frame: Baseline
Cohort B and Subcohort B1: ALT Levels at Index Diagnosis Date and Index Treatment Date
Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.
Time frame: Baseline
Cohort B and Subcohort B1: Total Bilirubin Level at Index Diagnosis Date and Index Treatment Date
Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.
Time frame: Baseline
Cohort B and Subcohort B1: QTc Interval at Index Diagnosis Date and Index Treatment Date
Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.
Time frame: Baseline
Cohort B and Subcohort B1: Neutrophil Count at Index Diagnosis Date and Index Treatment Date
Index diagnosis date is the date of first diagnosis of eBC. Index treatment date is the date of adjuvant ribociclib initiation.
Time frame: Baseline
Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Surgery
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration Between Surgery and Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Type of Surgery Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Type of BC Treatment Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration of Neoadjuvant and Adjuvant Therapy by Type, Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Year of ET Initiation, Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration of ET by Type, Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration of Other Cyclin-dependent Kinase 4/6 Inhibitor (CDK4/6i) Treatment by Type, Prior to Ribociclib Initiation
Time frame: Up to 40 months
Cohort A: Proportion of Patients by Baseline Demographics and Clinical Characteristics
Baseline characteristics (subject to data availability) include: * Age group * Sex * Race/ethnicity * Geographic region * Insurance type * Menopausal status * BMI category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * ECOG performance status * Estrogen and progesterone receptor status * HER2 IHC test results (0, 1+, 2+, 3+) * HER2 FISH test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * GI dysfunction (yes/no)
Time frame: Baseline
Cohort A: CCI
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases. It predicts the ten-year mortality for a patient who may have a range of comorbid conditions. CCI can be categorized as low (0-1) and high (≥2).
Time frame: Baseline
Cohort A: Duration Between Initial Diagnosis and Surgery
Time frame: Up to 58 months
Cohort A: Proportion of Patients by Type of Surgery
Time frame: Up to 58 months
Cohort A: Proportion of Patients by Type of BC Treatment Received
Time frame: Up to 58 months
Cohort A: Duration of Neoadjuvant and Adjuvant Therapy by Type
Time frame: Up to 58 months
Cohort A: Proportion of Patients by Year of ET Initiation
Time frame: Up to 58 months
Cohort A: Duration of ET by Type
Time frame: Up to 58 months
Cohort A: Duration of Other CDK4/6i Treatment by Type
Time frame: Up to 58 months
Cohort A: Proportion of Patients by Type of Concomitant Medication Received
Time frame: Up to 58 months
Cohort B and Subcohort B1: Proportion of Patients Who Switch to an Alternative CDK4/6i
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients Who Receive Concomitant Systemic and Local Oncology Therapies
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients Who Receive Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Duration of Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation, by Type of Therapy
Time frame: Up to 40 months
Cohort B and Subcohort B1: Time Between Discontinuation of Ribociclib and Start of Subsequent Systemic and Local Oncology Therapies, by Type of Therapy
Time frame: Up to 40 months
Cohort B and Subcohort B1: Initial Dose of Ribociclib
Time frame: Baseline
Cohort B and Subcohort B1: Proportion of Patients Who Undergo Ribociclib Dose Reduction
Time frame: Up to 40 months
Cohort B and Subcohort B1: Time to First Ribociclib Dose Reduction
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Reduction
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Dose Reduction
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients Who Experience Ribociclib Dose Interruption
Time frame: Up to 40 months
Cohort B and Subcohort B1: Time to First Ribociclib Dose Interruption
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Interruption
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Dose Interruption
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients Who Discontinue Ribociclib Treatment
Time frame: Up to 40 months
Cohort B and Subcohort B1: Time-to-Discontinuation (TTD) of Ribociclib Treatment
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Discontinuation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Discontinuation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Discontinuation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Persistence of Ribociclib Treatment
Persistence of ribociclib treatment, defined as the proportion of days covered (PDC) from the first prescription of ribociclib to data cut-off, discontinuation, or end of treatment.
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of Clinical Visits and/or Laboratory Assessments for Ribociclib Monitoring
Time frame: Up to 40 months
Cohort B and Subcohort B1: Cumulative Exposure to Ribociclib
Cumulative exposure to ribociclib, measured as the dose of ribociclib multiplied by days received for each prescription during the treatment duration (original dose to discontinuation).
Time frame: Up to 40 months
Subcohort B1: Incidence of Adverse Events (AEs) of Interest
AEs of interest include liver enzyme elevation, QT interval prolongation, neutropenia, fatigue, leukopenia, thrombocytopenia, anemia, infections, and interstitial lung disease/pneumonitis.
Time frame: Up to 6 months
Subcohort B1: Proportion of Patients Requiring Changes to the Ribociclib Regimen Following AE Occurrence
Changes to ribociclib regimen include dose reduction, dose interruption, treatment discontinuation, switching to another CDK4/6i, and initiating supportive therapies.
Time frame: Up to 6 months
Subcohort B1: Proportion of Patients by the Sequalae of AEs
Sequalae of AEs reported as follows: amelioration (improvement) of AE, progression of AE, resolution of AE, and recurrence of AE.
Time frame: Up to 6 months
Cohort B and Subcohort B1: Proportion of Patients Undergoing Drug-drug Interaction (DDI) Assessment Upon Ribociclib Initiation
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients With Actual DDIs
Actual DDIs will be defined based on clinical manifestation, assessed based on available data in each data set.
Time frame: Up to 40 months
Cohort B and Subcohort B1: Number of DDIs per Patient
Time frame: Up to 40 months
Cohort A: Proportion of Patients With Potential DDIs
Potential DDIs will be defined as concomitant administration of ribociclib with another drug that can potentially alter the efficacy and safety of the interacting treatments.
Time frame: Up to 58 months
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs
Potential DDIs will be defined as concomitant administration of ribociclib with another drug that can potentially alter the efficacy and safety of the interacting treatments.
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs Who Experience AEs
Time frame: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Clinical Monitoring Practices Before and After DDI Occurrence
Time frame: Up to 40 months
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by Demographics and Clinical Characteristics
Demographics and clinical characteristics include * Age group * Sex * Race/ethnicity * Geographic region * Insurance type * Menopausal status * BMI category * Alcohol use * Year of initial BC diagnosis * Tumor stage and grade * Clinical pathological node and tumor stage * Multiple breast primary diagnoses (yes/no) * ECOG performance status * Estrogen and progesterone receptor status * HER2 IHC test results (0, 1+, 2+, 3+) * HER2 FISH test (positive, negative) * Ki-67 category (positive, negative) * Genomic risk score * Hepatic dysfunction (yes/no) * Renal dysfunction (yes/no) * Cardiovascular disease (yes/no) * GI dysfunction (yes/no)
Time frame: Up to 40 months
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by BC Treatment Prior to Ribociclib
Time frame: Up to 40 months
Cohort B and Subcohort B1: Frequency of Ribociclib Treatment Modifications Related to DDIs
Treatment modifications include dose adjustments, interruptions, reductions, discontinuations, and switches to other therapies.
Time frame: Up to 40 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Jun 2028 and completion Sep 2026 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.